The power of R&D collaborations to improve outcomes in rare diseasesFar more common than initially thought, rare disease treatments remain far too scarce. The answer to the problem, Share XThe power of R&D collaborations to improve outcomes in rare diseaseshttps://pharmaphorum.com/webinars/pharma-research-outcomes-rare-diseases/
Using AI to make a big impact for emerging and mid-sized biopharma companiesWith recent market changes catalysing a rapid shift to an omnichannel approach, life science organisations of every size Share XUsing AI to make a big impact for emerging and mid-sized biopharma companieshttps://pharmaphorum.com/webinars/using-ai-to-make-a-big-impact-for-emerging-and-mid-sized-biopharma-companies/
The digital transformation of pharma’s physician engagement strategiesThe exact shape of healthcare’s post-COVID ‘new normal’ is still being framed, but it is clear that some Share XThe digital transformation of pharma’s physician engagement strategieshttps://pharmaphorum.com/webinars/digital-transformation-pharma-engagement-p360/
Customer engagement and pharma’s field force futureHow healthcare professionals (HCPs) prefer to engage with pharma companies has been changing for some time, and COVID’s Share XCustomer engagement and pharma’s field force futurehttps://pharmaphorum.com/webinars/axtria-customer-engagement-pharmas-field-force-future-digital-transformation/
Virtual trials and the next generation of pharma clinical researchPreviously viewed as a ‘nice to have’ for the pharma industry, virtual trials were already moving from a Share XVirtual trials and the next generation of pharma clinical researchhttps://pharmaphorum.com/webinars/nihr-virtual-trials-pharma-research/
Coordinating and delivering research in the pandemic: The UK approachThe acute phase of the COVID-19 pandemic tested the UK’s capacity and capability to rapidly deliver crucial clinical Share XCoordinating and delivering research in the pandemic: The UK approachhttps://pharmaphorum.com/webinars/uk-covid-coronavirus-research-nihr/
Increasing patient engagement with UK clinical trialsPharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so Share XIncreasing patient engagement with UK clinical trialshttps://pharmaphorum.com/webinars/uk-regulatory-pathway-patient-engagement-trials/
Introducing the new NIHR National Patient Recruitment CentresThe five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical Share XIntroducing the new NIHR National Patient Recruitment Centreshttps://pharmaphorum.com/webinars/nihr-national-patient-recruitment-centres/
Clinical decision-making insights for haem/oncsDespite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several Share XClinical decision-making insights for haem/oncshttps://pharmaphorum.com/oncology/clinical-decision-making-insights-haem-oncs/
